Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2020 22
2021 35
2022 33
2023 19
2024 11
2025 6
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Acute kidney injury in COVID-19 patients receiving remdesivir: A systematic review and meta-analysis of randomized clinical trials.
Shams G, Kazemi A, Jafaryan K, Morowvat MH, Peymani P, Karimzadeh I. Shams G, et al. Clinics (Sao Paulo). 2023 Apr 13;78:100200. doi: 10.1016/j.clinsp.2023.100200. eCollection 2023. Clinics (Sao Paulo). 2023. PMID: 37120984 Free PMC article.
OBJECTIVES: Remdesivir is an antiviral agent with positive effects on the prognosis of Coronavirus Disease (COVID-19). However, there are concerns about the detrimental effects of remdesivir on kidney function which might consequently lead to Acute …
OBJECTIVES: Remdesivir is an antiviral agent with positive effects on the prognosis of Coronavirus Disease (COVID-19). However, there …
Remdesivir Alleviates Acute Kidney Injury by Inhibiting the Activation of NLRP3 Inflammasome.
Yin L, Zhao H, Zhang H, Li Y, Dong Y, Ju H, Kong F, Zhao S. Yin L, et al. Front Immunol. 2021 May 21;12:652446. doi: 10.3389/fimmu.2021.652446. eCollection 2021. Front Immunol. 2021. PMID: 34093539 Free PMC article.
Acute kidney injury (AKI) is a frequent clinical complication in critically ill patients, and it rapidly develops into renal failure with high morbidity and mortality. However, other than dialysis, no effective therapeutic interventions can offer reliable tre …
Acute kidney injury (AKI) is a frequent clinical complication in critically ill patients, and it rapidly develops into …
COVID-19 and acute kidney injury.
Ertuğlu LA, Kanbay A, Afşar B, Elsürer Afşar R, Kanbay M. Ertuğlu LA, et al. Tuberk Toraks. 2020 Dec;68(4):407-418. doi: 10.5578/tt.70010. Tuberk Toraks. 2020. PMID: 33448738 Free article. Review. English.
Current data show that many hospitalized COVID-19 patients suffer from kidney damage, in the form of proteinuria, hematuria or acute kidney injury (AKI). AKI is especially prevalent among severe and critically ill COVID-19 patients and is a predictor o …
Current data show that many hospitalized COVID-19 patients suffer from kidney damage, in the form of proteinuria, hematuria or acu …
Acute kidney injury in patients with COVID-19: Epidemiology, pathogenesis and treatment.
Adamczak M, Surma S, Więcek A. Adamczak M, et al. Adv Clin Exp Med. 2022 Mar;31(3):317-326. doi: 10.17219/acem/143542. Adv Clin Exp Med. 2022. PMID: 35077034 Free article. Review.
The methods of treating the underlying disease, i.e., COVID-19 in patients with acute kidney injury and those without acute kidney injury are similar. However, it should be stressed that in the treatment of COVID-19 accompanied by acut …
The methods of treating the underlying disease, i.e., COVID-19 in patients with acute kidney injury and those without …
Acute Kidney Injury in COVID-19: The Chinese Experience.
Zheng X, Zhao Y, Yang L. Zheng X, et al. Semin Nephrol. 2020 Sep;40(5):430-442. doi: 10.1016/j.semnephrol.2020.09.001. Epub 2020 Sep 4. Semin Nephrol. 2020. PMID: 33334457 Free PMC article. Review.
Here, we review recently published studies on COVID-19-associated acute kidney injury (AKI) in China. The pooled incidence of AKI in all reported COVID-19 patients was 6.5%, with a much higher rate in patients from the intensive care unit (32.5%). ...Studies …
Here, we review recently published studies on COVID-19-associated acute kidney injury (AKI) in China. The pooled incide …
Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS.
Wu B, Luo M, Wu F, He Z, Li Y, Xu T. Wu B, et al. Front Pharmacol. 2022 Mar 25;13:692828. doi: 10.3389/fphar.2022.692828. eCollection 2022. Front Pharmacol. 2022. PMID: 35401177 Free PMC article.
Acute kidney injury (AKI) is a common complication among patients with the novel coronavirus (COVID-19). ...The mean time to AKI event onset was 4.91 7.25 days in COVID-19 cases with remdesivir therapy. The fatality proportion was 36.45% in AKI cases …
Acute kidney injury (AKI) is a common complication among patients with the novel coronavirus (COVID-19). ...The mean ti …
Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System.
Li X, Zhou L, Gaggl M, Kinlaw AC, Gou Z, Xu Y, Wei J, Wang T. Li X, et al. Int J Clin Pharm. 2023 Apr;45(2):509-514. doi: 10.1007/s11096-023-01554-4. Epub 2023 Mar 24. Int J Clin Pharm. 2023. PMID: 36964312 Free PMC article.
BACKGROUND: Evidence about remdesivir-associated acute kidney injury (AKI) among patients with novel coronavirus disease 2019 (COVID-19) was controversial. ...Number of signals in sensitivity analyses and the proportion of AKI in remdesivir-asso …
BACKGROUND: Evidence about remdesivir-associated acute kidney injury (AKI) among patients with novel coronavirus …
Remdesivir.
[No authors listed] [No authors listed] 2022 Feb 3. LiverTox®: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2022 Feb 3. LiverTox®: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 33211457 Free Books & Documents. Review.
Remdesivir is an antiviral nucleotide analogue used for therapy of severe novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS) coronavirus 2 (CoV-2) infection. Remdesivir therapy is given intravenously for 3 to 10 days …
Remdesivir is an antiviral nucleotide analogue used for therapy of severe novel coronavirus disease 2019 (COVID-19) caused by severe …
Baricitinib.
[No authors listed] [No authors listed] 2022 Aug 30. LiverTox®: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2022 Aug 30. LiverTox®: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643344 Free Books & Documents. Review.
Baricitinib is an orally available small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis, severe alopecia areata, and, in combination with remdesivir, severe COVID-19 in hospitalized patients requiring supplementary oxygen. …
Baricitinib is an orally available small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis, …
Safety of Remdesivir in Patients With Acute Kidney Injury or CKD.
Thakare S, Gandhi C, Modi T, Bose S, Deb S, Saxena N, Katyal A, Patil A, Patil S, Pajai A, Bajpai D, Jamale T. Thakare S, et al. Kidney Int Rep. 2021 Jan;6(1):206-210. doi: 10.1016/j.ekir.2020.10.005. Epub 2020 Oct 10. Kidney Int Rep. 2021. PMID: 33073066 Free PMC article. No abstract available.
115 results